Humana
HUM
$214.95
-1.13%
Humana Inc. is one of the largest private health insurers in the United States, operating within the Medical - Healthcare Plans industry. The company has built a distinct competitive identity by specializing in government-sponsored programs, with nearly all its medical membership derived from Medicare, Medicaid, and the military's Tricare program, complemented by healthcare services like primary care and pharmacy benefit management. The current investor narrative is dominated by the impact of regulatory changes on Medicare Advantage payments, with a recent, larger-than-expected 2027 payment increase from the Centers for Medicare & Medicaid Services (CMS) boosting sector-wide sentiment, though this follows a period of significant stock price volatility tied to underlying profitability concerns and quarterly earnings disappointments.…
HUM
Humana
$214.95
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Hold. The core thesis is that while the stock is deeply undervalued on a sales basis and has a positive regulatory catalyst, the severe and recent deterioration in profitability and cash flow requires a 'show me' period before confidence can be restored. Supporting evidence includes the exceptionally low PS ratio of 0.24, suggesting a deep discount to historical norms. Revenue growth remains robust at 11.3% YoY. However, this is counterbalanced by a Q4 net margin of -2.45%, negative quarterly free cash flow of -$1.85 billion, and a forward PE of 13.54 which may not be sustainable if earnings estimates are cut. The recent 20% rally shows sentiment improvement, but it follows a -47.54% drawdown. The thesis would upgrade to a Buy if the company demonstrates a clear return to profitability in the next quarter (Q1 2026), with gross margins stabilizing above 14% and positive free cash flow generation. It would downgrade to a Sell if the next earnings report shows another significant net loss or if the stock breaks below the $163 support level. Based on the current data, the stock appears fairly valued for the elevated level of risk it carries; it is not overvalued, but the discount is justified by the fundamental deterioration.
Sign up to view all
HUM 12-Month Price Forecast
The investment case for HUM is a binary bet on a profitability turnaround. The deep valuation discount (PS 0.24) and positive regulatory catalyst provide a margin of safety and a potential catalyst for upside. However, the severe deterioration in Q4 margins and cash flow cannot be ignored and suggests fundamental risk remains high. The base case of a slow, grinding recovery is most probable, leading to range-bound trading. The stance would upgrade to bullish on concrete evidence of margin stabilization in the next quarterly report, or downgrade to bearish on another significant earnings miss.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $279.44 and implied upside of +30.0% versus the current price.
Average Target
$279.44
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$172 - $279
Analyst target range
Analyst coverage appears limited, with only 6 analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the dataset. The institutional ratings show recent actions, with firms like RBC Capital downgrading from 'Outperform' to 'Sector Perform' and others like Barclays and Wells Fargo maintaining 'Equal Weight' or 'Hold' ratings in February 2026, while Goldman Sachs maintains a 'Sell'. This pattern suggests a neutral-to-cautious stance following the stock's decline and mixed fundamental news. The lack of a clear consensus target price and the minimal number of analysts indicate limited or fragmented institutional coverage, which is somewhat unusual for a company of Humana's market cap. This can lead to higher volatility and less efficient price discovery, as the stock may be more reactive to news flows and large block trades rather than sustained analyst-driven narratives. The recent news-driven rally on Medicare payment updates shows how sentiment can shift rapidly in such an environment.
Bulls vs Bears: HUM Investment Factors
The evidence currently leans bearish, as the severe deterioration in profitability and cash flow in Q4 2025 represents a fundamental crisis that outweighs the recent positive regulatory news and deep valuation discount. The bull case hinges entirely on a swift and sustainable recovery in margins, while the bear case is supported by concrete, recent financial data showing losses and cash burn. The single most important tension in the investment debate is whether the favorable 2027 Medicare payment update from CMS is sufficient to reverse the severe cost pressures and margin erosion that led to the Q4 loss, or if the profitability challenges are structural and persistent.
Bullish
- Deep Valuation Discount: The stock trades at a Price-to-Sales (PS) ratio of 0.24, a severe discount to its own historical range and typical for a major insurer, suggesting a potential value opportunity if profitability recovers. This multiple is near the bottom of its observable range, far below the PS above 2.0 seen in prior years.
- Regulatory Tailwind from CMS: A larger-than-expected 2027 Medicare Advantage payment increase from CMS has boosted sector-wide sentiment and revenue visibility, directly addressing a key investor concern. This news catalyzed a significant 1-month rally of +20.37% from the March lows.
- Strong Underlying Revenue Growth: Q4 2025 revenue grew 11.3% year-over-year to $32.52 billion, demonstrating resilient top-line demand despite profitability issues. The Insurance Segment generated $31.34 billion, showing the core business remains a significant revenue generator.
- Significant Relief Rally Underway: The stock has rallied +20.37% in the past month from its 52-week low of $163.11, indicating a potential trend reversal driven by positive news. The low beta of 0.445 suggests this move is driven by company-specific catalysts rather than broader market moves.
Bearish
- Severe Profitability Collapse: Q4 2025 saw a net loss of -$796 million and a gross margin compression to 11.67% from 14.27% in Q3, indicating deep-seated cost pressures. The net margin was -2.45%, and profitability has deteriorated sharply from a strong Q1 net income of $1.24 billion.
- Concerning Cash Burn: Free cash flow was -$1.85 billion in Q4 2025, and operating cash flow was -$1.65 billion, raising significant liquidity questions despite positive TTM FCF of $375 million. The current ratio of 0.72 suggests potential short-term liquidity pressure.
- Extreme Technical Downtrend: The stock is down -22.44% over the past year and -25.41% over six months, trading near 49% of its 52-week range. It experienced a peak-to-trough drawdown of approximately -47.54% from October 2025 to March 2026, reflecting deep fundamental concerns.
- Analyst Skepticism & Low Coverage: Recent analyst actions include downgrades to 'Sector Perform' and 'Hold', with Goldman Sachs maintaining a 'Sell'. Only 6 analysts provide estimates, indicating limited institutional coverage and potentially higher volatility due to less efficient price discovery.
HUM Technical Analysis
The stock is in a pronounced downtrend, evidenced by a 1-year price change of -22.44% and a 6-month decline of -25.41%. With a current price of $205.14, it is trading at approximately 49% of its 52-week range ($163.11 to $315.35), positioning it much closer to its lows than its highs, which suggests a potential value opportunity but also reflects deep-seated fundamental concerns that have driven the sell-off. Recent momentum shows a significant divergence, with a strong 1-month rally of +20.37% sharply contrasting the longer-term downtrend; this surge is likely a reaction to the favorable CMS Medicare payment news, indicating a potential relief rally or trend reversal attempt. However, the 3-month performance remains deeply negative at -24.93%, underscoring the severity of the preceding decline and the nascent stage of any recovery. Key technical levels are clearly defined, with immediate support at the 52-week low of $163.11 and major resistance at the 52-week high of $315.35. A sustained breakout above the recent recovery highs near $210 would signal strengthening bullish momentum, while a breakdown below the $163 support could trigger a new leg down. The stock's beta of 0.445 indicates it has been significantly less volatile than the broader market (SPY) during this turbulent period, which is unusual for a name experiencing such a large drawdown and suggests its moves have been driven by idiosyncratic, fundamental news rather than systemic risk. The price action reveals a dramatic peak-to-trough move, with the stock collapsing from around $284 in late October 2025 to a low near $163 in March 2026, a drawdown of approximately -47.54%. The recent rally from those March lows, including a +4.38% gain on the last trading day, has been vigorous but faces overhead supply from investors who bought at much higher prices. The low beta, coupled with this extreme price swing, highlights a stock caught in a fundamental re-rating, where company-specific news on Medicare rates and earnings is the primary driver, not broader market movements.
Beta
0.45
0.45x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$315
Price range past year
Annual Return
-18.5%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +24.8% | +8.5% |
| 3m | -19.3% | +2.8% |
| 6m | -26.0% | +4.6% |
| 1y | -18.5% | +32.3% |
| ytd | -18.7% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue growth remains robust on a year-over-year basis, with Q4 2025 revenue of $32.52 billion representing an 11.3% increase from the prior year. However, the quarterly trajectory reveals instability, as revenue slightly declined from $32.65 billion in Q3 2025, and the full-year trend shows pressure on underlying profitability despite top-line growth. The business is segmented, with the Insurance Segment generating $31.34 billion and the CenterWell Segment contributing $5.96 billion, indicating the core insurance operations drive the vast majority of sales, though healthcare services provide diversification. Profitability has deteriorated sharply, with the company reporting a net loss of -$796 million and a gross margin of only 11.67% for Q4 2025, a severe compression from the 14.27% gross margin in Q3. This follows a volatile pattern through 2025: a strong Q1 net income of $1.24 billion and Q2 income of $545 million were followed by a modest Q3 profit of $195 million before the deep Q4 loss. The net margin for the latest quarter was a dismal -2.45%, highlighting significant cost pressures or one-time charges that have overwhelmed revenue growth. The balance sheet and cash flow position show strain from the recent quarterly loss. The debt-to-equity ratio of 0.73 indicates a moderate level of leverage that is manageable for an insurer. However, free cash flow turned sharply negative in Q4 2025 at -$1.85 billion, and operating cash flow was -$1.65 billion, a concerning outflow. For context, trailing twelve-month free cash flow is positive at $375 million, but the quarterly cash burn raises liquidity questions. Return on equity (ROE) stands at 6.73%, which is low, reflecting the profitability challenges, while the current ratio of 0.72 suggests potential pressure on short-term liquidity.
Quarterly Revenue
$32.5B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$375000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given the company reported a net loss for the most recent quarter (Q4 2025 Net Income: -$796M), the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.24, while a forward-looking metric is not explicitly provided, but the low multiple reflects the market's severe discount on revenues due to evaporating profitability. The significant gap between the trailing PE ratio of 25.97 (which uses a marginal positive trailing EPS) and the deep quarterly loss underscores the earnings instability driving the valuation reset. Compared to industry averages, specific sector multiples are not provided in the data, but a PS ratio of 0.24 is exceptionally low for a major health insurer, typically suggesting a deep discount. This discount is directly justified by the company's recent plunge into losses, margin compression, and negative free cash flow generation in the latest quarter. The market is pricing in a material deterioration of the business model's profitability, likely due to Medicare cost pressures, outweighing the stable revenue growth. Historically, the stock's own valuation has collapsed. The current PS ratio of 0.24 is near the very bottom of its observable range, far below the PS ratios above 2.0 seen in 2021-2023 and even below the 0.95 recorded at the end of 2025. This indicates the stock is trading at a deep discount to its own historical sales multiple, which could signal a value opportunity if profitability is restored, but also reflects the market's belief that the fundamental deterioration is severe and perhaps persistent, not merely cyclical.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1073x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on collapsing profitability and cash generation. The Q4 2025 net loss of -$796 million and gross margin compression to 11.67% from 14.27% the prior quarter indicate the business model is under significant strain. This is compounded by a quarterly free cash flow burn of -$1.85 billion, raising liquidity concerns despite a manageable debt-to-equity ratio of 0.73. The company's heavy reliance on government-sponsored Medicare/Medicaid programs creates revenue concentration risk, making it highly sensitive to regulatory payment changes, as evidenced by the recent stock volatility. Market & Competitive Risks include valuation compression if the market determines the recent profitability collapse is not a one-time event. The stock's PS ratio of 0.24, while a deep discount, could remain depressed or fall further if margins do not recover. The low beta of 0.445 indicates its moves are idiosyncratic, driven by regulatory and earnings news, which can lead to sharp, unpredictable swings. Competitive pressure within the managed care sector and potential future regulatory headwinds from CMS beyond the 2027 update pose persistent external threats. Worst-Case Scenario involves a failure to stem the profitability decline, leading to consecutive quarterly losses, further cash burn, and a breach of liquidity covenants. This could trigger a loss of investor confidence, analyst downgrades, and a re-test of the 52-week low of $163.11. From the current price of $205.14, this scenario implies a realistic downside of approximately -20.5%. A more severe bear case, driven by a new negative regulatory development, could push the stock below the $163 support, potentially towards the $150 range, representing a loss of over -25%.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Continued profitability collapse and cash burn, as seen in Q4's -$796M net loss and -$1.85B free cash flow. 2) Regulatory Risk: Heavy dependence on Medicare/Medicaid means future CMS payment decisions can drastically impact revenue and margins. 3) Operational Risk: Inability to control medical costs and administrative expenses, leading to sustained margin compression. 4) Sentiment Risk: Low analyst coverage (6 analysts) and a history of earnings disappointments can lead to sharp, news-driven sell-offs, as shown by the -47.54% drawdown.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees a slow recovery, with the stock trading between $190 and $220. The Bull Case (25% probability), driven by a swift profit rebound, targets $250 to $280. The Bear Case (20% probability), involving further losses, sees a drop to $150-$163, re-testing the 52-week low. The Base Case is most likely, assuming the company returns to modest profitability but fails to achieve a full valuation re-rating. The key assumption is that Q1 2026 earnings show stabilization, not further deterioration.
HUM is deeply undervalued on a sales basis, trading at a Price-to-Sales (PS) ratio of 0.24, which is near the bottom of its historical range and exceptionally low for a major insurer. However, this discount is justified by its severe profitability crisis, as evidenced by a -2.45% net margin in Q4 2025. The forward PE of 13.54 appears reasonable but is unreliable given recent earnings volatility. The market is valuing HUM as a distressed asset, implying it expects persistent margin pressure. It is undervalued only if profitability normalizes.
HUM presents a high-risk, high-potential-reward opportunity that is only suitable for certain investors. The 25% implied upside to the base case target and the deep PS ratio of 0.24 are compelling for value seekers. However, the recent Q4 net loss of -$796 million and cash burn pose significant fundamental risks. It could be a good buy for investors who believe the CMS payment update will swiftly restore profitability and are willing to tolerate high volatility. Conservative investors should avoid it until profitability is demonstrably restored.
HUM is unsuitable for short-term trading due to its low beta (0.445) and idiosyncratic, news-driven volatility tied to earnings and regulatory updates. It is also a challenging long-term hold until its fundamental trajectory is clearer. The investment is best framed with a medium-term horizon of 12-24 months, allowing time for the next few quarterly reports to confirm or deny the profitability turnaround thesis. Given the lack of a significant dividend (yield 1.39%) and current earnings instability, it does not qualify as a reliable income stock. A minimum holding period of 12 months is suggested to assess the success of the recovery plan.